Who is sponsoring NCT00645060?

NCT00645060 is sponsored by City of Hope Medical Center.

What drugs are being tested in NCT00645060?

Interventions in NCT00645060: high performance liquid chromatography, pharmacological study, radionuclide imaging, single photon emission computed tomography, yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A.

What condition does NCT00645060 study?

NCT00645060 studies Unspecified Adult Solid Tumor, Protocol Specific.

Is NCT00645060 still recruiting?

NCT00645060 is currently completed. Last updated 27 February 2020.

Last reviewed 2020-02-27 · How we verify

NCT00645060

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A in Treating Patients With Advanced Solid Tumors

Completed Phase 1 Last updated 27 February 2020

What this trial tests

Phase 1 trial testing high performance liquid chromatography in Unspecified Adult Solid Tumor, Protocol Specific in 18 participants. Completed in 6 September 2016.

Timeline

9 October 2006

Primary endpoint
6 September 2016

6 September 2016

Quick facts

Lead sponsor	City of Hope Medical Center
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	9 October 2006
Primary completion	6 September 2016
Estimated completion	6 September 2016
Sites	1 location across United States

Drugs / interventions tested

high performance liquid chromatography
pharmacological study — full drug profile →
radionuclide imaging
single photon emission computed tomography
yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A

Conditions studied

Unspecified Adult Solid Tumor, Protocol Specific — all drugs for Unspecified Adult Solid Tumor, Protocol Specific →

Sponsor

City of Hope Medical Center

Who can join

Adults 18 to 120, any sex, with Unspecified Adult Solid Tumor, Protocol Specific. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Radiolabeled monoclonal antibodies, such as yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A, can find tumor cells and carry tumor-killing substances to them without harming normal cells. This may be an effective treatment for advanced cancer. PURPOSE: This phase I trial is studying the side effects and best dose of yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A in treating patients with advanced solid tumors.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Tumor-Specific Labeling of Pancreatic Cancer Using a Humanized Anti-CEA Antibody Conjugated to a Near-Infrared Fluorophore.
Lwin TM, Murakami T, Miyake K, Yazaki PJ, et al · · 2018 · cited 38× · PMID 29372363 · DOI 10.1245/s10434-018-6344-6
The development of fluorescence guided surgery for pancreatic cancer: from bench to clinic.
Lwin TM, Hoffman RM, Bouvet M. · · 2018 · cited 22× · PMID 29768067 · DOI 10.1080/14737140.2018.1477593
Fluorescent humanized anti-CEA antibody specifically labels metastatic pancreatic cancer in a patient-derived orthotopic xenograft (PDOX) mouse model.
Lwin TM, Miyake K, Murakami T, DeLong JC, et al · · 2018 · cited 15× · PMID 30647873 · DOI 10.18632/oncotarget.26484
Radiometals in Imaging and Therapy: Highlighting Two Decades of Research.
Sharma S, Pandey MK. · · 2023 · cited 13× · PMID 37895931 · DOI 10.3390/ph16101460
CEACAM5-Targeted Immuno-PET in Androgen Receptor-Negative Prostate Cancer.
Imberti C, De Gregorio R, Korsen JA, Hoang TT, et al · · 2024 · cited 7× · PMID 38782457 · DOI 10.2967/jnumed.123.267107

Verify or expand the search:

Other trials of high performance liquid chromatography

Trials testing the same drug.

NCT00667121 — Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopr · completed
NCT01206465 — Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors · Phase 1 · completed
NCT00770471 — ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme · Phase 1 · completed
NCT00959244 — Study of Urine Samples From Women With Newly Diagnosed Breast Cancer Enrolled on Clinical Trial UNMC-08105 · completed
NCT00738452 — Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Stage I-IIIB Non-Small Cell Lung Cancer After Complet · Phase 1 · completed

Other recruiting trials for Unspecified Adult Solid Tumor, Protocol Specific

Currently open trials in the same condition.

NCT02112565 — RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Stand · Phase 1 · active not recruiting
NCT02293954 — Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer · NA · active not recruiting
NCT00477958 — Assessment Tool for Older Patients With Cancer · NA · active not recruiting

Other City of Hope Medical Center trials

Trials by the same sponsor.

NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07218692 — RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy · Phase 2 · not yet recruiting
NCT07363408 — Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment · Phase 1 · not yet recruiting
NCT07226102 — Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic o · NA · withdrawn
NCT07225855 — Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Can · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00645060 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by City of Hope Medical Center
Last refreshed: 27 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00645060.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing